Investigational Drug Information for Camostat
✉ Email this page to a colleague
What is the development status for investigational drug Camostat?
Camostat is an investigational drug.
There have been 24 clinical trials for Camostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 1st 2020.
The most common disease conditions in clinical trials are COVID-19, Coronavirus Infections, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Stanford University, Yale University, and Bayer.
There are one hundred and fifty-two US patents protecting this investigational drug and zero international patents.
Summary for Camostat
| US Patents | 152 |
| International Patents | 2,603 |
| US Patent Applications | 1,011 |
| WIPO Patent Applications | 497 |
| Japanese Patent Applications | 167 |
| Clinical Trial Progress | Phase 2 (2020-05-01) |
| Vendors | 28 |
Recent Clinical Trials for Camostat
| Title | Sponsor | Phase |
|---|---|---|
| Camostat Mesylate for Protein-losing Enteropathy After Fontan Operation | Seoul National University Hospital | Phase 2 |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications | Ono Pharmaceutical Co. Ltd | Phase 1/Phase 2 |
| The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications | Yale University | Phase 1/Phase 2 |
Clinical Trial Summary for Camostat
Top disease conditions for Camostat
Top clinical trial sponsors for Camostat
US Patents for Camostat
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Camostat | ⤷ Sign Up | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof | Signature Therapeutics, Inc. (San Carlos, CA) | ⤷ Sign Up |
| Camostat | ⤷ Sign Up | Substituted pyridines and method of use | AbbVie S.a.r.l. (Luzembourg, LU) Galapagos NV (Mechelen, BE) | ⤷ Sign Up |
| Camostat | ⤷ Sign Up | Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity | Parion Sciences, Inc. (Durham, NC) | ⤷ Sign Up |
| Camostat | ⤷ Sign Up | Crystallization method and bioavailability | GRUNENTHAL GMBH (DE) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Camostat
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Camostat | Australia | AU2010293028 | 2029-09-08 | ⤷ Sign Up |
| Camostat | Brazil | BR112012005124 | 2029-09-08 | ⤷ Sign Up |
| Camostat | Canada | CA2773340 | 2029-09-08 | ⤷ Sign Up |
| Camostat | China | CN102695545 | 2029-09-08 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
